Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Share-based Compensation (2020 - 2025)

Historic Share-based Compensation for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Q3 2025 value amounting to $4.5 million.

  • 4D Molecular Therapeutics' Share-based Compensation fell 3036.98% to $4.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.0 million, marking a year-over-year decrease of 167.28%. This contributed to the annual value of $26.1 million for FY2024, which is 3280.45% up from last year.
  • 4D Molecular Therapeutics' Share-based Compensation amounted to $4.5 million in Q3 2025, which was down 3036.98% from $5.0 million recorded in Q2 2025.
  • 4D Molecular Therapeutics' 5-year Share-based Compensation high stood at $7.6 million for Q4 2024, and its period low was $2.3 million during Q1 2021.
  • Over the past 5 years, 4D Molecular Therapeutics' median Share-based Compensation value was $4.5 million (recorded in 2022), while the average stood at $4.9 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first skyrocketed by 26798.46% in 2021, then plummeted by 3036.98% in 2025.
  • 4D Molecular Therapeutics' Share-based Compensation (Quarter) stood at $3.7 million in 2021, then grew by 16.48% to $4.3 million in 2022, then skyrocketed by 36.06% to $5.9 million in 2023, then grew by 28.16% to $7.6 million in 2024, then plummeted by 40.37% to $4.5 million in 2025.
  • Its last three reported values are $4.5 million in Q3 2025, $5.0 million for Q2 2025, and $7.0 million during Q1 2025.